[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cohort-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cohort-study":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,75,106,137,160,182,212,236,260,286],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100344715","apache-cohort-a-psoriatic-arthritis-cohort-100344715",false,"NCT03768271","APACHE Cohort (A Psoriatic Arthritis CoHort)","French Cohort on the Becoming of Recent Articular Psoriatic Rheumatism (A Psoriatic Arthritis CoHort)","APACHE","Inclusion Criteria:\n\n* Women or men aged from 18 to 65 inclusive\n* First episode of peripheral arthritis in the last 12 months, authenticated by a rheumatologist\n* Psoriasis diagnosed by a practitioner or family history of psoriatic arthritis (first-degree relative \\[parent or sibling\\] or second degree relative)\n* Arthritis most likely recognized as a psoriatic arthritis by a rheumatologist (diagnostic confidence score : ≥ 7 out of 10)\n* Signed informed consent form\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Formal diagnostic of inflammatory rheumatism other than psoriatic arthritis\n* Treatment or history of treatment with a biomedicine\n* Patient receiving csDMARDS (methotrexate, sulfasalazine, or leflunomide) or apremilast treatment over the past year for rheumatological symptoms\n* Oral steroids in the last 4 weeks, above 10 mg\u002Fd of prednisone or with modified dosage\n* intravenous or intra articular steroids in the last 4 weeks\n* IRM contraindication\n* Cognitive, mental or psychic disorders impeding protocol accomplishment\n* Difficulties with French language understanding\n* Patient under tutorship or curatorship\n* Pregnancy","ALL","18 Years","65 Years",{"count":21,"type":22},425,"ESTIMATED","OBSERVATIONAL","Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoriasis or familial psoriasis. PsA can be a very disabling disease through progressive and irreversible joint damage. Long-term functional prognosis of patients with PsA is correlated with the presence and severity of the radiographic joint lesions of the disease.\n\nHowever, the proportion of patients who will develop those peripheral joint damages is not yet known and less over the factors which are associated\u002Finvolved in such an aggressive pattern of the disease. Early identification of this subgroup of patients is particularly important for determining early \"intensive\" treatment, strict management with a Treat To Target approach, and identification of new treatments with a stronger structural effect.\n\nThe main objective of this prospective 10 years cohort is to describe the 5 years structural (radiographic) severity of recent Psoriatic arthritis (PsA)with recent peripheral arthritis.Some of the secondary objectives are to describe the 10 years structural severity within those patients, and to determine the predictive factors of those 5 and 10 years radiographic lesions (genetic, environmental, clinic, therapeutic factors).\n\nAPACHE will provide a unique longitudinal standardized database concerning patients with PsA with very recent peripheral arthritis. Research projects which will based on those collected data should allow to identify the mechanisms of aggressive joint damage, to highlight mew treatments targets, to better describe the burden of the disease, to test previous or develop new assessments tolls, to develop early diagnostic criteria",[26,27,28],"Cohort Study","Psoriatic Arthritis (PsA)","Recent Peripheral Arthritis",[30,31,32],"radiographic lesions","10 years cohort","Psoriatic arthritis","RECRUITING","2026-04-22",{"date":36,"type":37},"2026-04-27","ACTUAL",{"date":39,"type":37},"2020-02-12",{"date":41,"type":22},"2036-12-01",{"name":43,"class":44},"Assistance Publique - Hôpitaux de Paris","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100620828","a-cohort-study-of-the-efficacy-and-safety-of-biologics-in-patients-with-abpa-100620828","NCT07362693","A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).\n2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.\n3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.\n4. Blood eosinophil count ≥150 cells \u002FμL.\n5. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;\n2. Known allergic history to biological agents;\n3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;\n4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n5. Pregnant or lactating women;\n6. Currently participating in other interventional clinical research;\n7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":54,"type":22},50,"2 Years","To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.",[58,59,60,26,61,62],"ABPA","Biologics","Allergic Bronchopulmonary Aspergillosis (ABPA)","Allergic Bronchopulmonary Aspergillosis","Efficacy and Safety",[64,61,59],"abpa","2026-04-16",{"date":67,"type":37},"2026-04-17",{"date":69,"type":37},"2025-01-31",{"date":71,"type":22},"2028-12-31",{"name":73,"class":44},"Qianfoshan Hospital",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100617682","osteoporotic-vertebral-compression-fracture-cohort-study-100617682","NCT07321795","Osteoporotic Vertebral Compression Fracture Cohort Study","Osteoporotic Vertebral Compression Fractures: A Multi-center Cohort Study Based on Disease and Syndrome Differentiation","Inclusion Criteria:\n\n1.50 years ≤ age \\\u003C 80 years; gender includes both male and female. 2.Meet the diagnostic criteria for new-onset osteoporotic vertebral compression fracture.\n\n3.Voluntarily participate in this clinical study and sign the informed consent form.\n\nSubjects meeting only criteria (1) and (3) with a T-score ≥ -1.0 can be included in the normal bone mass group. Subjects meeting criteria (1) and (3) with -2.5 \\\u003C T-score \\\u003C -1.0 can be included in the osteopenia group. Subjects meeting criteria (1) and (3) with T-score ≤ -2.5, meeting the diagnostic criteria for osteoporosis, can be included in the OP group. Subjects meeting all criteria (1), (2), and (3) will be included in the OVCF patient group.\n\nExclusion Criteria:\n\n1. Patients with serious concomitant cardiovascular\u002Fcerebrovascular diseases, liver\u002Fkidney diseases, malignant tumors, or other wasting diseases, and patients with infectious diseases.\n2. Patients with other endocrine system diseases, such as Cushing's syndrome, hyperthyroidism, hypothyroidism, etc.\n3. Patients who have participated in other clinical trials within the past 3 months.\n4. Patients with concomitant Alzheimer's disease, mental illnesses or depression, or those unable to cooperate to complete the trial.\n5. Patients with poor compliance",true,"50 Years","80 Years",{"count":86,"type":22},200,"The study aims to construct an early warning model for Osteoporotic Vertebral Compression Fracture (OVCF) by integrating TCM syndrome patterns with modern risk factors. This is a multi-center cohort study on OVCF integrated with disease and syndrome differentiation in Traditional Chinese Medicine (TCM).",[89,26],"OVCF Database",[91,92,93,94],"Osteoporotic Vertebral Compression Fractures","Traditional Chinese Medicine","Potential biomarkers","Risk prediction model","NOT_YET_RECRUITING","2026-01-07",{"date":98,"type":37},"2026-01-09",{"date":100,"type":22},"2026-01-10",{"date":102,"type":22},"2027-12-31",{"name":104,"class":44},"Wangjing Hospital, China Academy of Chinese Medical Sciences",4,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":82,"sex":17,"minAge":4,"maxAge":114,"enrollmentInfo":115,"targetDuration":117,"studyType":23,"phases":4,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100612162","respiratory-infections-in-young-children-100612162","NCT07249996","Respiratory Infections in Young Children","Respiratory Infections in Young Children in Colombia and Panamá: Epidemiology, Interactions, and Long-term Consequences.","MINERVAL","Inclusion Criteria:\n\n* Newborns younger than 29 days of life, with or without pre-existing conditions\n* Infants whose parent(s) or guardian(s) are available for telephone contact for the duration of the study, and do not intend to relocate outside of the study area, to ensure adherence to RTI and in-person visits.\n* Infants whose parent(s) or guardian(s) provide informed consent to participate in the study.\n* Infants whose parent(s) or guardian(s) are willing to authorize data and specimen collection, storage and analysis.\n\nExclusion Criteria:\n\n* Infants born to a pregnant mother under 14 years of age (under Colombian law, pregnancies occurring in individuals younger than 14 years of age are legally presumed to result from sexual abuse).","29 Days",{"count":116,"type":22},1088,"5 Years","The goal of this observational study is to learn about the causes, severity, and long-term effects of respiratory tract infections (RTIs) in young children from birth to five years of age in Colombia and Panamá. The main questions it aims to answer are:\n\nHow often do respiratory infections occur in children under two years old, and which viruses or bacteria cause them? Why do some children develop more severe infections than others? Do early infections or vaccinations change how the immune system responds to future illnesses? How do viruses and bacteria interact in the respiratory tract to influence disease severity and long-term respiratory health? Researchers will follow newborns from birth until age five to understand how respiratory infections develop and affect children's health over time. Participants will not receive any experimental treatment.\n\nFamilies who join the study will:\n\nBe contacted twice a week through a phone app or phone calls to check for symptoms of respiratory infection.\n\nAttend in-person visits if their child becomes ill and every six months for routine follow-up.\n\nProvide nasal and blood samples during illness episodes so researchers can identify the viruses or bacteria causing infection and study how the immune system responds.\n\nThis study began in May 2024 and is being conducted in Cali, Colombia, and Panamá City, Panamá. The research team plans to continue to include participants and continue active follow-up until the children reach five years of age.\n\nThe information collected will help scientists and health professionals understand how different pathogens cause respiratory infections, what factors increase the risk of severe illness, and how early infections may influence long-term lung health. The study's findings will support future efforts to prevent and treat respiratory diseases in young children.",[120,121,122,26],"Respiratory Tract Infections (RTI)","Lower Respiratory Tract Infection (LRTI)","Viral Infections",[124,125,126],"Birth Cohort Study","Respiratory Tract Infection (RTI)","Children","2025-11-24",{"date":129,"type":37},"2025-11-25",{"date":131,"type":37},"2024-05-02",{"date":133,"type":22},"2031-12-30",{"name":135,"class":44},"Eduardo Lopez -Medina",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":144,"targetDuration":145,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":74},"100610902","risks-and-benefits-of-radiofrequency-ablation-for-chronic-venous-insufficiency-ceap-c3-c6-in-patients-aged-80-and-over-100610902","NCT07233616","Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over","Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over: A Prospective Single-Arm Cohort Study","Inclusion Criteria:\n\n1. Age: Aged 80 years or older.\n2. Clinical Diagnosis: Symptomatic chronic venous insufficiency of the lower extremity, with the highest clinical class (CEAP classification) being one of the following:\n\n   * C3: Venous edema\n   * C4a: Pigmentation or eczema\n   * C4b: Lipodermatosclerosis or atrophie blanche\n   * C5: Healed venous ulcer\n   * C6: Active venous ulcer\n3. Confirmed Reflux: Color duplex ultrasound examination confirming reflux (reflux time \\> 0.5 seconds) in the great saphenous vein (GSV) and\u002For small saphenous vein (SSV) of the target limb.\n4. Informed Consent: The patient or their legally authorized representative is able to understand and voluntarily provides written informed consent.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria will be excluded from the study:\n\n  1. Mobility: Non-ambulatory or bedridden.\n  2. Thrombosis: Presence of acute superficial thrombophlebitis of the target vein, or deep vein thrombosis (DVT) in the target limb.\n  3. Arterial Disease: Significant peripheral arterial disease, defined as an ankle-brachial index (ABI) \\\u003C 0.8 in the target limb.\n  4. Coagulopathy: Uncorrectable coagulation disorder.\n  5. Allergy: Known severe allergy to local anesthetics (e.g., lidocaine) or relevant device materials.\n  6. Cognition \\& Compliance: Severe cognitive impairment or psychiatric illness that, in the investigator's judgment, precludes adequate understanding and cooperation for the study procedures and follow-up.\n  7. Life Expectancy: Life expectancy of less than 1 year due to other comorbid conditions (e.g., terminal malignancy).\n  8. General Unsuitability: Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.",{"count":54,"type":22},"6 Months","The prevalence of severe chronic venous insufficiency (CVI) is significant in the growing octogenarian population. While radiofrequency ablation (RFA) is a standard minimally invasive treatment, robust data on its outcomes and safety profiles specifically in patients aged 80 years and older remain scarce. This study aims to evaluate the risks and benefits of RFA in this specific, high-risk demographic.This prospective, single-arm, single-center cohort study will enroll 50 patients (initial target sample size) aged ≥80 years with CVI classified as CEAP C3 to C6 and with confirmed great or small saphenous vein reflux. All participants will undergo endovenous RFA under tumescent local anesthesia. The primary outcomes are: 1) the great\u002Fsmall saphenous vein occlusion rate at 6 months, assessed by duplex ultrasonography, and 2) the change in disease-specific quality of life from baseline to 6 months, measured by the Aberdeen Varicose Vein Questionnaire (AVVQ). Secondary outcomes include occlusion rates at 1 and 3 months; complication rates (e.g., deep vein thrombosis, skin burns, paresthesia) within 30 days; and changes in the Venous Clinical Severity Score (VCSS) and the 12-Item Short Form Health Survey (SF-12) at predefined intervals over 6 months.This study is designed to demonstrate a high technical success rate (occlusion rate \\>95% at 6 months) and a statistically significant improvement in AVVQ and VCSS scores at 6 months post-procedure. The collected data will provide a detailed profile of complication rates, characterizing the safety of RFA in this very elderly cohort.This study will provide crucial, prospective evidence regarding the efficacy and safety of RFA for treating CVI in octogenarians. The findings are expected to guide clinical decision-making and inform treatment guidelines for this vulnerable and expanding patient population.",[148,149,150,26],"Chronic Venous Insufficiency, CVI","Radiofrequency Ablation","Octogenarians(Aged 80 and Over)","2025-11-16",{"date":153,"type":37},"2025-11-18",{"date":155,"type":37},"2025-10-01",{"date":157,"type":22},"2026-09-01",{"name":159,"class":44},"Chengdu University of Traditional Chinese Medicine",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":74},"100608923","tianshan-community-cohort-establishment-and-follow-up-100608923","NCT07207863","Tianshan Community Cohort Establishment and Follow-up","The Cardiac and Panvascular Medicine Diagnosis and Treatment Center, People's Hospital of Xinjiang Uygur Autonomous Region,","Inclusion Criteria:\n\n1. Residents \\>=18y\n2. Permanent residents or individuals who have lived in the region for more than 5 years and are enrolled in local social security medical insurance\n3. Residents without severe physical disability and capable of normal communication\n4. Residents whose diseases and deaths are monitored and managed by the local health authorities\n5. Residents who voluntarily participate and provide written informed consent\n\nExclusion Criteria:\n\n1. Temporary residents or floating population\n2. Residents with severe health conditions that prevent participation in the study\n3. Residents who are unwilling to undergo follow-up assessments for the study",{"count":168,"type":22},1000000,"This population-based cohort study on disease prevention and health promotion was established in northwest China, leveraging data from routine annual health examinations. Initiated in January 2016, the cohort enrolled nearly all residents aged 18 years and older who were registered at community healthcare centers. The program was developed to provide a comprehensive framework for disease prevention and community health promotion, with the aim of producing population-based evidence across a broad spectrum of diseases in the general population. At baseline, data were collected on participant demographics, medical and family histories, disability status, living environment, and blood biochemical parameters. Follow-up information is primarily obtained through chronic disease management programs, annual health examinations, and electrical health records. Cause-specific mortality is ascertained from local death registration systems. Biological specimens, questionnaire data, and electrical health records are systematically archived in the Biobank and Big Data Center of the People's Hospital of Xinjiang Uygur Autonomous Region.",[26,171,172],"Natural Population","Northwest Region of China","2025-09-27",{"date":175,"type":37},"2025-10-06",{"date":177,"type":37},"2016-01-01",{"date":179,"type":22},"2035-12-31",{"name":181,"class":44},"People's Hospital of Xinjiang Uygur Autonomous Region",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100584057","doac-versus-vka-in-patients-with-non-high-risk-aps--prospective-cohort-study-100584057","NCT06884384","DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","Direct Oral Anticoagulants Versus Warfarin in Patients With Non-high-risk Antiphospholipid Syndrome : Prospective Cohort Study","DOWAPS","Inclusion Criteria:\n\n* Persons who have received full information about the organization of the research and have given their oral consent to participate.\n* Male or female 18 years of age or older;\n* Carrier of venous thrombotic SAPL:\n\n  * Not favoured by a major or ≥ 2 minor favouring factors, if the patient doesn't present with obstetrical SAPL in accordance with the ACR\u002FEULAR 2023 clinical classification criteria.\n  * Or favored by ≥ 2 minors, if the patient has obstetrical SAPL: severe preeclampsia \\\u003C 34 weeks or placental insufficiency\n  * Regardless of how long the disease has been present\n  * With persistent positivity of at least one biological criterion:\n\n    * Positivity of circulating lupus anticoagulant or IgG anticardiolipid or IgG anti-beta-2GPI\n    * And persistence of the same positive test ≥ 12 weeks apart\n    * And With maximum delay of positivity of the 1st antiphospholipid test of 3 years after the thrombotic event\n* Current anticoagulant treatment, regardless of date of introduction\n\n  * rivaroxaban or apixaban\n  * or antivitamin K\n* Patient affiliated to a social security system\n\nExclusion Criteria:\n\n* Venous thrombotic event motivating current anticoagulant treatment favoured by a major favouring factor:\n\n  * Active cancer\n  * Hospitalization with bed rest for at least 3 days in the 3 months preceding the event\n  * Major trauma with fractures or spinal cord injury in the month preceding the event\n  * Surgery with general\u002Fspinal\u002Fepidural anesthesia for \\> 30 minutes in the 3 months preceding the event.\n* In the absence of a history of pre-eclampsia or placental insufficiency: venous thrombotic event motivating current anticoagulant treatment favoured by 2 or more minor favouring factors:\n\n  * Systemic autoimmune disease or active inflammatory bowel disease\n  * Acute\u002Fsevere infection\n  * Central venous catheter in the same vascular bed\n  * Hormone replacement therapy, estrogenic oral contraceptives, or hormone-stimulating therapy in progress\n  * Long-distance travel (≥ 8 hours)\n  * Obesity (BMI ≥ 30 kg\u002Fm²)\n  * Pregnancy or post-partum (6 weeks after delivery)\n  * Prolonged immobilization\n  * Surgery with general\u002Fspinal\u002Fepidural anesthesia for \\\u003C 30 minutes in the 3 months preceding the event\n* Known triple antiphospholipid positivity\n* Isolated IgM antiphospholipid positivity\n* History of known arterial thrombosis\n* History of known microcirculatory thrombosis\n* Known SAPL-related cardiac valvular disease\n* Persons referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code\n* Persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care under articles L. 3212-1 and L. 3213-1.\n* Glomerular filtration rate \\\u003C 30ml\u002Fmin.\n* Weight \\\u003C 50kg\n* History of thrombotic recurrence under well-administered anticoagulant therapy.",{"count":191,"type":22},310,"Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier handling and lower bleeding risk for equivalent efficacy. In APS, VKAs are still the reference treatment. However, DOACs are generally introduced in the acute phase of venous, before the diagnosis of APS. VKA have the disadvantage of numerous food and drug interactions, and therefore require close monitoring of INR, at least once a month. Because they are easier to use than VKAs, and the risk of bleeding is lower, patients are often reluctant to switch from DOACs to VKA. Studies have shown that APS patients with high thrombotic risk (positivity of all three antiphospholipid tests, history of arterial or small vessels thrombosis or cardiac valve damage) have an increased thrombotic risk during DOACs vs. VKA treatment. Since 2020, the ISTH guidelines have suggested avoiding DOACs in high-risk APS, but suggest continuing theim in other patients if they were introduced for venous thrombosis and if follow-up on DOACs is reassuring. In the case of high-risk APS patients, the relay is therefore systematic. For non-high-risk patients (the majority), there are no data to justify systematic switch. Given the quality-of-life advantages of DOACs over VKAs, patients are not always in favor of changing their anticoagulant therapy, especially if they have been on it for many years with good tolerability. For these reasons, a number of patients with non-high-risk APS remain on DOACs. Nevertheless, the limited data available on the efficacy of DOACs in non-high-risk patients are of low level of evidence and contradictory. In 2020, a literature review of non-high-risk SAPL patients treated with DOACs reported that 8.6% of them experienced thrombotic recurrence within 12 months, with no possible comparison with VKAs. A recent retrospective study with 96 patients reported that 15.4% of patients treated with DOACs had a recurrence, compared to 5.3% on VKAs. However, this difference was not statistically significant (p=0.15) due to a clear lack of power. The objective is to determine the frequency of thrombotic recurrences and to compare it according to the type of oral treatment, anti-Xa versus VKA, in non-high-risk APS, through a cohort study with prospective follow-up. The patient's usual antithrombotic treatment, DOAC and VKA, will be continued unchanged.",[194,26,195],"Antiphospholipid Syndrome (APS)","Thrombotic and Bleeding Events",[197,198,199,200,201],"Antiphospholipid Syndrome","VKA treatment","DOAC Treatment","biological analysis","Thrombotic and bleeding events","2025-06-11",{"date":204,"type":37},"2025-06-13",{"date":206,"type":22},"2025-09-15",{"date":208,"type":22},"2031-09-15",{"name":210,"class":44},"Central Hospital, Nancy, France",13,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100587710","recall-of-a-cohort-of-subjects-in-the-mediterranean-area-monitoring-of-liver-diseases-nutrihep-3-100587710","NCT06931925","Recall of a Cohort of Subjects in the Mediterranean Area. Monitoring of Liver Diseases (NUTRIHEP 3).","Nutrihep3","Inclusion Criteria:\n\n* \\>18 Years\n* Resident of Putignano (BA -Italy)\n\nExclusion Criteria:\n\n* \\\u003C 18 years",{"count":220,"type":22},2300,"Liver diseases represent a significant public health problem, with a high prevalence and a growing incidence worldwide, and a significant impact on global morbidity and mortality, causing approximately 2 million deaths annually.\n\nDeaths are largely attributable to complications of cirrhosis and hepatocellular carcinoma.\n\nThe most common causes of cirrhosis worldwide are related to viral hepatitis, alcohol, and non-alcoholic fatty liver disease caused by poor dietary habits.\n\nRegarding the hepatitis B virus (HBV), the vaccination program, together with the improvement of socioeconomic conditions and greater public awareness, have progressively reduced the incidence and prevalence of this viral disease. Chronic hepatitis related to the hepatitis C virus (HCV), after an increase in the 1980s and 1990s, is showing a decreasing trend, particularly among younger age groups. While other studies have focused on liver diseases of metabolic origin, the most recent epidemiological data concerning the Italian population were collected in the late 1990s. Since a decade has now passed, it was thought that it might be interesting to collect new data on the prevalence pattern of liver diseases, especially in southern Italy, particularly in a municipality equally geographically distant from both the coast and the inland. Therefore, this observational study aims to analyze the evolution of liver diseases through the recall of a cohort of patients already identified in the Mediterranean area. The cohort is composed of individuals residing in the municipality of Putignano (BA) who have already undergone evaluation of liver function, comorbidities and dietary habits, in addition to adding genetic information through genome-wide association (GWAS) analyses, useful for identifying associations between genetic variants and specific phenotypic characteristics",[26],[26,224,225,226],"GWAS","MASLD","Liver Diseases","2025-04-17",{"date":229,"type":37},"2025-04-22",{"date":231,"type":22},"2025-09-01",{"date":233,"type":22},"2027-09-01",{"name":235,"class":44},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":74},"100567817","respiratory-disease-cohort-studies-of-chinese-medicine-for-pulmonary-nodule-100567817","NCT06673121","Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule","Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule （RESEARCH-PN）","Inclusion Criteria:\n\n① Patients with pulmonary nodules and recommended for follow-up by MDT; ② Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n①Patients with metastatic pulmonary nodules; ②Patients with benign diseases such as pulmonary lymph nodes, hamartomas, sclerosing alveolar cell tumors, or nodules with obvious benign features such as calcification; ③Patients withserious heart, lung, liver and kidney diseases.",{"count":244,"type":22},5000,"This study is a prospective multicenter cohort study that primarily evaluates the impact of traditional Chinese medicine treatment on pulmonary nodules",[247,26,92],"Pulmonary Nodule",[249,250,92],"Pulmonary nodule","Cohort study","2024-11-01",{"date":253,"type":37},"2024-11-04",{"date":255,"type":37},"2024-01-03",{"date":257,"type":22},"2029-12-30",{"name":259,"class":44},"Third Affiliated Hospital of Henan University of Traditional Chinese Medicine",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":74},"100543387","natural-course-and-therapeutic-effect-of-recurrent-acute-pancreatitis-100543387","NCT06355206","Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis","Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis: a Prospective Cohort Study","NACRE","Inclusion Criteria:\n\n* Patients with recurrent acute pancreatitis.\n\nExclusion Criteria:\n\n* Unwilling or unable to provide consent.",{"count":269,"type":22},2000,"The goal of this observational cohort study is to learn about the etiology, natural course, therapeutic effect and outcome of recurrent acute pancreatitis patients. The main question it aims to answer is:\n\nDoes endoscopic intervention, surgery or conservative treatment reduce the recurrence of acute pancreatitis? What are the risk factors affecting the recurrence of acute pancreatitis?\n\nPatients will be closely followed and clinical information will be recorded.",[26,272],"Recurrent Acute Pancreatitis",[274,275,276],"recurrent acute pancreatitis","natural course","therapeutic effect","2024-05-07",{"date":279,"type":37},"2024-05-09",{"date":281,"type":37},"2024-04-22",{"date":283,"type":22},"2034-12",{"name":285,"class":44},"Changhai Hospital",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":17,"minAge":294,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":74},"100426960","northeastern-taiwan-community-medicine-research-cohort-100426960","NCT04839796","Northeastern Taiwan Community Medicine Research Cohort","A Cohort Study on Disease Prevention and Health Promotion in Northeastern Region of Taiwan","NTCMRC","Inclusion Criteria:\n\n1. Residing in Keelung city and new Taipei city.\n2. Mobile health and mental health\n3. Participating in healthcare outreaches\n\nExclusion Criteria:\n\n1. Under 20 years old\n2. Participant without judgment\n3. Participant has HIV","20 Years",{"count":296,"type":22},20000,"The cohort study on disease prevention and health promotion in the northeastern region of Taiwan is a trial dedicated to large-scale generational research in northeastern Taiwan beginning in the August of 2013. The program aims to develop a comprehensive and integrated approach to disease prevention and community health. The researcher's cohort organizes healthcare outreaches for participants over the age of 20 residing in 64 administrative areas in Keelung city and new Taipei city. The researcher's sessions include a comprehensive health examination, health-related questionnaires, and disease awareness seminars.\n\nBiological samples, questionnaire information, and medical data obtained from researcher's participants are stored in researcher's core laboratory. Depersonalized data and samples are shared with partnering trials approved by the Chang Gung Memorial Hospital Institutional review board. The investigators are currently partnered with 18 clinical trials spanning across multiple disciplines such as urology, hepatology, metabolism, physical therapy, and psychology.",[26],[292,300,301],"Maintenance Project","Health Care Activities","2021-04-07",{"date":304,"type":37},"2021-04-09",{"date":306,"type":37},"2013-08",{"date":308,"type":22},"2043-08",{"name":310,"class":44},"Chang Gung Memorial Hospital"]